Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05947136 | PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.(PASCA -MM) | recruiting | N/A | 204 | Centre Leon BerardOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642362 | Digital Support for Multiple Myeloma Quality of Life(DigiMyQoL) | recruiting | N/A | 108 | CareAcrossINDUSTRY |
| 1 |
| Jun 11, 2026 |
| clinicaltrials |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | recruiting | Phase 3 | 510 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06559033 | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS(GAMY) | recruiting | — | 300 | University Hospital, RouenOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07519187 | CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms | recruiting | Early Phase 1 | 20 | The General Hospital of Western Theater CommandOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05776979 | Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07018050 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | recruiting | Phase 2 | 160 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03858205 | Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | recruiting | N/A | 100 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05405387 | Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant(IMPACT) | recruiting | Phase 2 | 120 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT06974786 | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma(FASTER) | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07255898 | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07490613 | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma | recruiting | Phase 1 | 99 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07581704 | Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | recruiting | Phase 1 | 10 | Christopher StrouseOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05145400 | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 50 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04776395 | Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 68 | Emory UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07226934 | An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers | recruiting | N/A | 40 | Washington University School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04211259 | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | recruiting | Early Phase 1 | 70 | Rutgers, The State University of New JerseyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04508790 | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease(KOALA) | recruiting | Phase 1 | 12 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609030 | A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma | recruiting | N/A | 90 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609576 | Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. | recruiting | — | 350 | Infanta Leonor University HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07052916 | A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 228 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05011045 | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06433947 | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Opna Bio LLCINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05853965 | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma(BELI(E)VE) | recruiting | Phase 1 / Phase 2 | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)(ROTATE) | recruiting | Phase 2 | 50 | Noffar BarOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07283224 | Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma | recruiting | — | 600 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 261 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT07582354 | MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity | recruiting | — | 520 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | recruiting | Early Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT02269592 | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | recruiting | — | 10,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07448935 | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS(ALPS) | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07226609 | A Dietary Study for People With Multiple Myeloma | recruiting | N/A | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07564219 | BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma(BEAM-MM) | recruiting | N/A | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07446777 | FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease(FAST-M) | recruiting | N/A | 120 | University of MiamiOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04888039 | Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"(VAMOS) | recruiting | — | 2,000 | University Hospital, ToulouseOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06679829 | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | recruiting | Phase 2 | 215 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06988020 | "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma(MM-ZTE-II) | recruiting | N/A | 45 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2026source: clinicaltrials